All In Biotech

Drug Trial Radar · NCT05886920

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

67

Planned (sponsor's estimate)

Start

Jul 10, 2023

Primary completion

Aug 2028

Study completion Aug 2028

Sponsor

Lead sponsor
D3 Bio (Wuxi) Co., LtdIndustry
Sponsor type
Industry
First posted
Jun 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.

Conditions

  • Advanced Solid Tumors With MAPK Pathway Mutations

Interventions

  • D3S-002Drug

    Oral Tablet

  • D3S-001Drug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: First dose until 30 days after the last dose (or specified in the protocol)
  2. Maximum tolerated dose (MTD) based on Dose limiting toxicities (DLTs)Time frame: First dose up to 24 months
  3. Recommended Phase 2 dose (RP2D)Time frame: First dose up to 24 months

Locations

18 sites in 4 countries. Site status is shown where the registry gives one.

  • D3 Bio Investigative Site

    Detroit, Michigan · Recruiting

  • D3 Bio Investigative Site

    New York, New York · Completed

  • D3 Bio Investigative Site

    Nashville, Tennessee · Recruiting

  • D3 Bio Investigative Site

    Houston, Texas · Recruiting

  • D3 Bio Investigative Site

    Blacktown, New South Wales, Australia · Completed

  • D3 Bio Investigative Site

    Macquarie Park, New South Wales, Australia · Recruiting

  • D3 Bio Investigative Site

    Bedford Park, South Australia, Australia · Completed

  • D3 Bio Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • D3 Bio Investigative Site

    Nedlands, Western Australia, Australia · Completed

  • D3 Bio Investigative Site

    Beijing, Beijing Municipality, China · Recruiting

  • D3 Bio Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • D3 Bio Investigative Site

    Harbin, Heilong Jiang, China · Suspended

  • D3 Bio Investigative Site

    Wuhan, Hubei, China · Recruiting

  • D3 Bio Investigative Site

    Shanghai, Shanghai Municipality, China · Recruiting

  • D3 Bio Investigative Site

    Shanghai, Shanghai Municipality, China · Active not recruiting

  • D3 Bio Investigative Site

    Chengdu, Sichuan, China · Recruiting

  • D3 Bio Investigative Site

    Hangzhou, Zhejiang, China · Recruiting

  • D3 Bio Investigative Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.